| Objective Macular edema is often mostly secondary to diabetic retinopathy and retinal vein occlusion. It will cause severe damage to central vision, which is an main cause of vision loss in patients. Using ranibizumab to treat macular edema has become a hot research topic. This study aim to observe and compare the effection of the ranibizumab intravitreal injection between DME and RVO-ME. Methods 26 cases, 33 eyes in our research; including 17 DME eyes, 16 RVO-ME eyes. Case inclusion criteria:(1)Optic coherence tomography(OCT) examination showed central macular thickness>300μm.(2)Fundus fluorescein angiography(FFA) confirmed macular edema.(3)Exclude previously received grid photocoagulation, anti-VEGF therapy or intraocular surgical treatment.(4)Exclude other ocular diseases which lead to visual impairment, such as macular membrane and glaucoma.(5)Exclude ranibizumab injection contraindications. All patients are asked to keep blood pressure and blood glucose in a normal range. All of them will be informed the risk and complications of ranibizumab and sign informed consent before treatment. Every patient received ranibizumab 0.05 ml intravitreal injection. The follow-up duration was 1 day, 2 weeks and 4 weeks after the injection. The best corrected visual acuity(BCVA) and central macular thickness(CST) were observed and compared in DME patients and RVO-ME patients between the before injection and after injection. Results The BCVA was obviously improved at 1 day, 2 weeks and 4 weeks after injection in both groups in comparison with before injection(p<0.05). CST of two groups were significantly relieved than pre-injection(p<0.05). BCVA and CST were no significant difference in the groups of DME and RVO-ME(p>0.05). Conclusion Using ranibizumab-intravitreal-injection to treatment of DME and RVO-ME can reduce macular edema and improve the visual activity. The curative effect of ranibizumab intravitreal injection has no significant difference between DME and RVO-ME. |
PDF Full Text Request